CASI

CASI Pharmaceuticals Inc

CASI.US casipharmaceuticals.com + Research + Basket
CIK 0000895051
Employees 233
Phone 86 10 6508 6063
Fiscal year end December
IPO Jun 11, 1996
Address 1701-1702, China Central Office Tower 1, Beijing, China, 100025
Price N/A
USD · NASDAQ
52-week range
0.21
1.48
Market Cap
4.26M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-1.39
Div. Yield
N/A
% Institutions
32.60%
% Insiders
87.27%

1 Year

-89.6%

3 Year

-87.1%

10 Year

-96.9%
Description

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Actions

Add an action for CASI.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Alexander A. Zukiwski M.D. Executive VP & Chief Medical Officer 1957
Dr. Wei Zhang Ph.D. Senior Vice President 1960
Mr. David A. Cory M.B.A., R.Ph. CEO & Director 1964
Ms. Kun Qian VP & Global Controller 1982
Ms. Chunhua Wang Chief Operating Officer 1972
Ms. Wei Gao General Counsel 1982
Dr. Ingrid C. Choong Ph.D. Head of Corporate Development NA
Dr. James E. Goldschmidt Ph.D. Chief Business Officer NA
Mr. Hai Huang Chief Commercial Officer & GM 1969
Dr. Junping Chen Chief Medical Officer of China NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Sep 08, 2022 James Huang N/A Purchase 33.30K $4.28 $142.52K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
VR Adviser, LLC 987.26K Dec 31, 2025 4.80% $0.04 0.00%
Bank of America Corp 254.88K Sep 30, 2025 1.24% $0.00 2,013.29%
Woodline Partners LP 133.41K Dec 31, 2025 0.65% $0.00 -19.46%
Renaissance Technologies Corp 43.10K Dec 31, 2025 0.21% $0.00 -1.82%
Two Sigma Investments LLC 23.79K Dec 31, 2025 0.12% $0.00 -28.50%
Geode Capital Management, LLC 18.81K Dec 31, 2025 0.09% $0.00 0.00%
Citadel Advisors Llc 14.05K Dec 31, 2025 0.07% $0.00 0.00%
Royal Bank of Canada 9.95K Sep 30, 2025 0.05% $0.00 -50.00%
Wells Fargo & Co 505.00 Sep 30, 2025 0.00% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 365.00 Sep 30, 2025 0.00% $0.00 0.00%
BlackRock Inc 296.00 Sep 30, 2025 0.00% $0.00 0.00%
BNP Paribas Arbitrage, SA 134.00 Dec 31, 2025 0.00% $0.00 0.00%
SIMPLEX TRADING, LLC 133.00 Dec 31, 2025 0.00% $0.00 0.00%
JPMorgan Chase & Co 50.00 Sep 30, 2025 0.00% $0.00 100.00%
UBS Group AG 14.00 Sep 30, 2025 0.00% $0.00 -98.53%
Colonial Trust Co / SC 11.00 Dec 31, 2025 0.00% $0.00 0.00%
Mccormack Advisors International 5.00 Dec 31, 2025 0.00% $0.00 0.00%
Ground Swell Capital, LLC 0.00 Dec 31, 2025 0.00% $0.00 -100.00%
Susquehanna International Group, LLP 0.00 Sep 30, 2025 0.00% $0.00 -100.00%
Wellington Shields & Co., LLC 0.00 Dec 31, 2025 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Nasdaq Composite Index 18.81K 0.09% ▲ 0.00% Jan 31, 2026

Financial Highlights

▼
Market Cap: $4.26M
EBITDA: $-42.27M
PEG Ratio: $0.00
Book Value: $-1.39
Earnings/Share: $-3.02
Profit Margin: -183.96%
Operating Margin: -333.14%
ROA (TTM): -61.80%
ROE (TTM): -1,094.50%
Revenue (TTM): $26.85M
Revenue/Share (TTM): $1.62
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -60.50%

Valuation Metrics

Enterprise Value: $16.66M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 20.55M
Shares Float: 9.31M
% Insiders: 87.27%
% Institutions: 32.60%
Shares Short: 100.12K
Shares Short (Prior Month): 60.76K
Short Ratio: 2.44
Short % Float: 0.54%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$28.54M
Cost of Goods Sold
adjust
$-17.39M
Gross Profit
subtotal
$11.15M
SG&A
adjust
$-23.58M
R&D
adjust
$-8.92M
Other Operating Expense
adjust
$-18.27M
Operating Income
subtotal
$-39.62M
Other / Non-Operating Items
adjust
$363.00K
Net Income
subtotal
$-39.26M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CASI.US!